6505--Buspirone RFP

The Department of Veterans Affairs National Acquisition Center is seeking to establish a pharmaceutical supply contract for Buspirone HCL Tablets through solicitation 36E79725R0024. The procurement will cover eight line items of Buspirone tablets in various strengths and package sizes, with the intention of supplying multiple federal agencies including the Department of Veterans Affairs, Department of Defense, Indian Health Service, Bureau of Prisons, and State Veteran Homes. Contractors must provide FDA-approved products, maintain current Good Manufacturing Practices (cGMP) certification, and submit a unique National Drug Code (NDC) number for each line item. The evaluation will consider technical and past performance factors, with the contract to be awarded to the most advantageous offeror. Proposals are due by May 8, 2025, at 2:30 PM CT, with a 0.5% Cost Recovery Fee to be included in pricing.

The solicitation is an unrestricted procurement with a small business size standard of 1,300 employees, and the contract will span a base year with four one-year option periods. Distribution will be managed through Pharmaceutical Prime Vendor contractors, with McKesson Corporation serving as the VA and DoD Prime Vendor. Estimated annual usage varies by tablet strength, with the highest volume being 179,623 bottles of Buspirone HCL 10mg Tablets in 500-count bottles. Contractors must comply with strict cybersecurity, privacy, and information system security requirements, including mandatory training and data protection protocols. The procurement falls under NAICS Category 325412 (Pharmaceutical Preparation Manufacturing) and PSC Category 6505 (Drugs And Biologicals), with one aggregate award planned to cover all line items. Contractors will be required to maintain specific insurance coverage, including workers' compensation, general liability, and automobile liability insurance.